Skip to content
News Center
About Us Careers News Center Contact Us Legal Doing Business with Illumina Investors Illumina for Startups Customer Engagement Center

Press Releases

Date Title
Mar 5, 2026 Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering
Feb 27, 2026 Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida
Feb 25, 2026 Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
Feb 24, 2026 Illumina launches TruPath Genome, setting a new standard in genomic insight
Feb 23, 2026 Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility
Feb 17, 2026 Illumina To Webcast Upcoming Investor Conference
Feb 5, 2026 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
Feb 3, 2026 Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally
Jan 30, 2026 Illumina completes acquisition of SomaLogic
Jan 20, 2026 Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology
Jan 13, 2026 Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
Jan 13, 2026 Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025
Jan 12, 2026 Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026
Jan 8, 2026 Illumina Appoints Dr. Eric Green as Chief Medical Officer
Jan 6, 2026 Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2026 Illumina, Inc. All rights reserved.